Carl Friedrich Beuchel

Carl Friedrich Beuchel


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2020 in Metabolites
Verified
Journal Article
Open access
PDF file
JHJosephin Hirschel
Josephin Hirschel
MVMandy Vogel
Mandy Vogel
RBRonny Baber
Ronny Baber
Andrea GartenAndrea Garten
Andrea Garten
CBCarl Friedrich Beuchel
Carl Friedrich Beuchel
Uta CeglarekUta Ceglarek
Uta Ceglarek
Background: Changes in the metabolic fingerprint of blood during child growth and development are a largely under-investigated area of research. The examination of such aspects requires a cohort of healthy children and adolescents who have been subjected to deep phenotyping, including collection of biospecimens for metabolomic analysis. The present study considered whether amino acid (AA) and acylcarnitine (AC) concentrations are associated with age, sex, body mass index (BMI), and puberty during childhood and adolescence. It also investigated whether there are associations between amino acids (AAs) and acylcarnitines (ACs) and laboratory parameters of glucose and lipid metabolism, as well as liver, kidney, and thyroid parameters. Methods: A total of 3989 dried whole blood samples collected from 2191 healthy participants, aged 3 months to 18 years, from the LIFE Child cohort (Leipzig, Germany) were analyzed using liquid chromatography tandem mass spectrometry to detect levels of 23 AAs, 6 ACs, and free carnitine (C0). Age- and sex-related percentiles were estimated for each metabolite. In addition, correlations between laboratory parameters and levels of the selected AAs and ACs were calculated using hierarchical models. Results: Four different age-dependent profile types were identified for AAs and ACs. Investigating the association with puberty, we mainly identified peak metabolite levels at Tanner stages 2 to 3 in girls and stages 3 to 5 in boys. Significant correlations were observed between BMI standard deviation score (BMI-SDS) and certain metabolites, among them, branched-chain (leucine/isoleucine, valine) and aromatic (phenylalanine, tyrosine) amino acids. Most of the metabolites correlated significantly with absolute concentrations of glucose, glycated hemoglobin (HbA1c), triglycerides, cystatin C (CysC), and creatinine. After age adjustment, significant correlations were observed between most metabolites and CysC, as well as HbA1c. Conclusions: During childhood, several AA and AC levels are related to age, sex, BMI, and puberty. Moreover, our data verified known associations but also revealed new correlations between AAs/ACs and specific key markers of metabolic function.

3 October 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MZMartijn Zoodsma
Martijn Zoodsma
CBCarl Friedrich Beuchel
Carl Friedrich Beuchel
SYSummaira Yasmeen
Summaira Yasmeen
LKLeonhard Kohleick
Leonhard Kohleick
ANAakash Nepal
Aakash Nepal
CLClaudia Langenberg
Claudia Langenberg
Genetic studies of human metabolism have been limited in scale and allelic breadth. Here we provide a data-driven map of the genetic regulation of circulating small molecules and lipoprotein characteristics (249 traits) measured using proton nuclear magnetic resonance spectroscopy across the allele frequency spectrum in ~450,000 individuals. Trans-ancestral meta-analyses identify 29,824 locus–metabolite associations mapping to 753 regions with effects largely consistent between men and women and large ancestral groups represented in UK Biobank. We observe and classify extreme genetic pleiotropy, identify regulators of lipid metabolism, and assign effector genes at >100 loci through rare-to-common allelic series. We propose roles for genes less established in metabolic control (for example, SIDT2), genes characterized by phenotypic heterogeneity (for example, APOA1) and genes with specific disease relevance (for example, VEGFA). Our study demonstrates the value of broad, large-scale metabolomic phenotyping to identify and characterize regulators of human metabolism.

9 October 2025 in Molecular Systems Biology
Verified
Journal Article
Open access
MPMaik Pietzner
Maik Pietzner
CBCarl Friedrich Beuchel
Carl Friedrich Beuchel
KDKamil Demircan
Kamil Demircan
JAJulian Hoffmann Anton
Julian Hoffmann Anton
WZWenhuan Zeng
Wenhuan Zeng
CLClaudia Langenberg
Claudia Langenberg
Proteomic techniques now measure thousands of proteins circulating in blood at population scale, but successful translation into clinically useful protein biomarkers is hampered by our limited understanding of their origins. Here, we use machine learning to systematically identify a median of 20 factors (range: 1-37) out of >1800 participant and sample charateristics that jointly explained an average of 19.4% (max. 100.0%) of the variance in plasma levels of ~3000 protein targets among 43,240 individuals. Proteins segregated into distinct clusters according to their explanatory factors, with modifiable characteristics explaining more variance compared to genetic variation (median: 10.0% vs 3.9%), and factors being largely consistent across the sexes and ancestral groups. We establish a knowledge graph that integrates our findings with genetic studies and drug characteristics to guide identification of potential drug target engagement markers. We demonstrate the value of our resource by identifying disease-specific biomarkers, like matrix metalloproteinase 12 for abdominal aortic aneurysm, and by developing a widely applicable framework for phenotype enrichment (R package: https://github.com/comp-med/r-prodente ). All results are explorable via an interactive web portal ( https://omicscience.org/apps/prot_foundation ).

27 February 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
CBCarl Friedrich Beuchel
Carl Friedrich Beuchel
JDJulia Dittrich
Julia Dittrich
JPJanne Pott
Janne Pott
SHSylvia Henger
Sylvia Henger
FBFrank Beutner
Frank Beutner
MSMarkus Scholz
Markus Scholz
A variety of atherosclerosis and cardiovascular disease (ASCVD) phenotypes are tightly linked to changes in the cardiac energy metabolism that can lead to a loss of metabolic flexibility and to unfavorable clinical outcomes. We conducted an association analysis of 31 ASCVD phenotypes and 97 whole blood amino acids, acylcarnitines and derived ratios in the LIFE-Adult (n = 9646) and LIFE-Heart (n = 5860) studies, respectively. In addition to hundreds of significant associations, a total of 62 associations of six phenotypes were found in both studies. Positive associations of various amino acids and a range of acylcarnitines with decreasing cardiovascular health indicate disruptions in mitochondrial, as well as peroxisomal fatty acid oxidation. We complemented our metabolite association analyses with whole blood and peripheral blood mononuclear cell (PBMC) gene-expression analyses of fatty acid oxidation and ketone-body metabolism related genes. This revealed several differential expressions for the heart failure biomarker N-terminal prohormone of brain natriuretic peptide (NT-proBNP) in peripheral blood mononuclear cell (PBMC) gene expression. Finally, we constructed and compared three prediction models of significant stenosis in the LIFE-Heart study using (1) traditional risk factors only, (2) the metabolite panel only and (3) a combined model. Area under the receiver operating characteristic curve (AUC) comparison of these three models shows an improved prediction accuracy for the combined metabolite and classical risk factor model (AUC = 0.78, 95%-CI: 0.76–0.80). In conclusion, we improved our understanding of metabolic implications of ASCVD phenotypes by observing associations with metabolite concentrations and gene expression of the mitochondrial and peroxisomal fatty acid oxidation. Additionally, we demonstrated the predictive potential of the metabolite profile to improve classification of patients with significant stenosis.

30 April 2026 in Nature Medicine
Verified
Journal Article
Open access
KDKamil Demircan
Kamil Demircan
JCJulia Carrasco-Zanini
Julia Carrasco-Zanini
AWAlice Williamson
Alice Williamson
CBCarl Friedrich Beuchel
Carl Friedrich Beuchel
LJLinsey Jackson
Linsey Jackson
CLClaudia Langenberg
Claudia Langenberg
New obesity medications have demonstrated efficacy in trials, but their real-world deployment is partly limited by the absence of approaches that identify individuals for treatment based on risks for obesity-related complications. Here we present a risk prediction model to guide prioritization of high-risk individuals. In a population-based sample of ~200,000 individuals with a body mass index (BMI) exceeding 27 kg m − 2 , our machine learning framework identified the 20 most informative features, from among thousands tested, that predict future onset of 18 complications of obesity, providing information beyond BMI. An integrated model (OBSCORE) successfully stratified individuals into risk groups based on incidence over 10 years: for example, 5.7%, 1.8%, 0.9%, 0.4% and 0.1% for cardiovascular mortality. We demonstrate generalizability of the model in independent populations of European and non-European ancestry and, in SURMOUNT-1 trial participants, show that weight loss was similar across baseline OBSCORE risk groups and that predicted risks decreased following treatment with tirzepatide. In summary, OBSCORE provides a framework for prioritizing high-risk individuals with overweight or obesity based on their risk of obesity-related complications, complementing BMI-based frameworks.

2 February 2025 in medRxiv
Verified
Preprint
Open access
PDF file
MZMartijn Zoodsma
Martijn Zoodsma
CBCarl Friedrich Beuchel
Carl Friedrich Beuchel
SYSummaira Yasmeen
Summaira Yasmeen
LKLeonhard Kohleick
Leonhard Kohleick
ANAakash Nepal
Aakash Nepal
CLC Claudia Langenberg
C Claudia Langenberg
Genetic studies of human metabolism identified unknown disease processes and novel metabolic regulators, but have been limited in scale and allelic breadth. Here, we provide a data-driven map of the genetic regulation of circulating small molecules and lipoprotein characteristics (249 metabolic traits) measured using protein nuclear magnetic resonance spectroscopy (1H-NMR) across the allele frequency spectrum in ∼450.000 individuals. In trans-ancestry analyses, we identify 29,824 locus–metabolite associations mapping to 753 regions with effects largely consistent between men and women and major ancestral groups represented in UK Biobank. We develop a framework for classifying the observed extreme genetic pleiotropy, enabling identification of upstream ‘master’ regulators of lipid metabolism (’proportional pleiotropy’), such as ANGPTL3. We establish rare-to-common allelic series by integrating machine-learning guided effector gene assignments with rare exonic variant analyses providing high confidence gene assignments at >100 loci, including less established regulators of lipid metabolism like SIDT2. At 17 such loci we observed phenotypic heterogeneity among variants mapping to the same gene indicating differential metabolic roles of the altered gene product. We identify VEGFA as a potential modulator of HDL-mediated risk for coronary artery disease. Our results demonstrate how rare-to-common genetic variation combined with deep molecular profiling can identify unknown and inform on poorly understood regulators of human metabolism to guide prevention and treatment of diseases.